- Home
- CERE
as 07-26-2024 4:00pm EST
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 7.5B | IPO Year: | N/A |
| Target Price: | $42.67 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Hold | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.59 - $44.60 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cerevel Therapeutics Holdings Inc. (CERE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COLES N ANTHONY | CERE | Director | Jun 3 '24 | Sell | $40.61 | 50,000 | $2,030,520.00 | 15,638 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | May 10 '24 | Sell | $42.10 | 50,000 | $2,105,125.00 | 15,638 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Apr 1 '24 | Sell | $42.33 | 50,000 | $2,116,640.00 | 15,638 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Mar 4 '24 | Sell | $41.01 | 50,000 | $2,050,550.00 | 15,638 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Feb 29 '24 | Sell | $41.16 | 50,000 | $2,057,890.00 | 15,638 | SEC Form 4 |
| Renger John | CERE | Chief Scientific Officer | Feb 6 '24 | Sell | $41.54 | 2,161 | $89,776.80 | 6,370 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Feb 6 '24 | Sell | $41.54 | 2,506 | $104,109.51 | 15,638 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Jan 2 '24 | Sell | $42.24 | 50,000 | $2,111,815.00 | 2,704 | SEC Form 4 |
| Sanchez Ramiro | CERE | Chief Medical Officer | Dec 26 '23 | Sell | $42.47 | 10,000 | $424,700.00 | 14,673 | SEC Form 4 |
| DiPietro Kenneth | CERE | Chief Human Resources Officer | Dec 22 '23 | Sell | $41.45 | 8,000 | $331,608.00 | 24,663 | SEC Form 4 |
| Bodenrader Mark | CERE | See Remarks | Dec 19 '23 | Sell | $41.42 | 7,889 | $326,787.62 | 17,724 | SEC Form 4 |
| DiPietro Kenneth | CERE | Chief Human Resources Officer | Dec 19 '23 | Sell | $41.42 | 6,256 | $259,143.54 | 24,663 | SEC Form 4 |
| Tregoning Kathleen | CERE | See Remarks | Dec 19 '23 | Sell | $41.42 | 6,288 | $260,469.08 | 7,516 | SEC Form 4 |
| ALTSCHULLER Susan | CERE | Chief Financial Officer | Dec 19 '23 | Sell | $41.42 | 13,808 | $571,971.55 | 16,913 | SEC Form 4 |
| Sanchez Ramiro | CERE | Chief Medical Officer | Dec 19 '23 | Sell | $41.42 | 10,152 | $420,528.33 | 14,673 | SEC Form 4 |
| Akamine Scott | CERE | Chief Legal Officer | Dec 19 '23 | Sell | $41.42 | 7,072 | $292,944.87 | 7,237 | SEC Form 4 |
| Sanchez Ramiro | CERE | Chief Medical Officer | Dec 15 '23 | Sell | $41.39 | 7,500 | $310,392.75 | 0 | SEC Form 4 |
| Sanchez Ramiro | CERE | Chief Medical Officer | Dec 7 '23 | Sell | $41.37 | 10,000 | $413,700.00 | 0 | SEC Form 4 |
| Akamine Scott | CERE | Chief Legal Officer | Dec 5 '23 | Sell | $35.00 | 7,500 | $262,500.00 | 513 | SEC Form 4 |
| Akamine Scott | CERE | Chief Legal Officer | Dec 5 '23 | Sell | $41.37 | 10,000 | $413,700.00 | 513 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Nov 14 '23 | Sell | $25.13 | 22,824 | $573,455.28 | 2,704 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Nov 7 '23 | Sell | $25.02 | 27,076 | $677,555.24 | 2,704 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Nov 7 '23 | Sell | $25.16 | 100 | $2,516.00 | 2,704 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Nov 2 '23 | Sell | $25.19 | 38,599 | $972,239.33 | 2,704 | SEC Form 4 |
| COLES N ANTHONY | CERE | Director | Nov 2 '23 | Sell | $25.43 | 61,401 | $1,561,458.13 | 2,704 | SEC Form 4 |
Latest Cerevel Therapeutics Holdings Inc. News
CERE Breaking Stock News: Dive into CERE Ticker-Specific Updates for Smart Investing
The Wall Street Journal
3 months ago
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
GlobeNewswire
3 months ago
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
NFL Highlights
6 months ago
Purdy on how SF's experience with 'backs against wall' helps in adversity
Insider Monkey
6 months ago
12 Best American Bank Stocks To Buy According to Analysts
ACCESSWIRE
6 months ago
Embracing What is Possible: Meet Megan Roder
Zacks
6 months ago
Company News for Feb 2, 2024
Thomson Reuters StreetEvents
6 months ago
Q4 2023 Huntington Ingalls Industries Inc Earnings Call
Insider Monkey
6 months ago
15 Navies with the Most Submarines in the World
Compare CERE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CERE Cerevel Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.